11:02:38 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-14 Bokslutskommuniké 2024
2024-11-14 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-05-30 Årsstämma 2024
2024-05-17 Kvartalsrapport 2024-Q1
2024-03-01 Ordinarie utdelning CSMED 0.00 DKK
2024-02-14 Bokslutskommuniké 2023
2023-12-15 Ordinarie utdelning CSMED 0.00 DKK
2023-07-18 Kvartalsrapport 2023-Q3
2023-05-17 Kvartalsrapport 2023-Q2
2023-04-14 Extra Bolagsstämma 2023
2023-02-17 Kvartalsrapport 2023-Q1
2023-02-14 Årsstämma 2023
2023-02-10 Ordinarie utdelning CSMED 0.00 DKK
2022-11-18 Bokslutskommuniké 2022
2022-08-13 Kvartalsrapport 2022-Q3
2022-05-20 Kvartalsrapport 2022-Q2
2022-02-18 Kvartalsrapport 2022-Q1
2021-12-10 Ordinarie utdelning CSMED 0.00 DKK
2021-12-09 Årsstämma 2022
2021-11-18 Bokslutskommuniké 2021

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriLäkemedel & Handel
CS Medica är ett danskt medicintekniskt bolag, dedikerat till läkemedelsforskning, utveckling, tillverkning och global kommersialisering. Bolaget blandar vetenskap och natur för att förbättra patienters liv med cannabinoidterapier för smärtlindring, och för att hantera autoimmuna och stressrelaterade symtom. Globalt erbjuder CS Medica CBD-behandlingar över disk (OTC), inklusive patenterade medicinska produkter, MHRA och MDR-registrerade artiklar, under varumärket CANNASEN® eller med egen märkning.
2023-02-13 13:30:11

CS MEDICA A/S ("CS MEDICA" or the "Company") announces today that the Company has entered into an agreement with the financial advisor Kapital Partner in Denmark.  With this cooperation, the company secures valuable insights and guidance on financial decisions and strategies as well as assistance in sourcing financial partners and maximizing shareholder value.

As an efficient OTC alternative, CS MEDICA is currently first mover to bridge R&D with patent-pending products registered as medical devices with cannabidiol under the pharmaceutical regulation, Medical Device Directive (MDD), now transitioning to Medical Device Regulation (MDR).

For individuals, who seek efficient and cleaner treatments over the counter, CS MEDICA revolutionizes with innovative products and technology within the cannabis and medical industries. From discovery to manufacturing, the company commits to improving people's lives with world-changing products that make a difference.

To secure and capitalize on CS MEDICA's first mover status, the company has entered into an agreement with the financial advisor Kapital Partner regarding the following services:
  • Financial strategy
  • Sourcing of strategic and financial partners
  • Market Relations
  • Market compliance

Lone Henriksen, CEO CS MEDICA comments;

"We are happy to announce that we have chosen a new financial advisor who will assist us in our funding of different growth stages, and financial decisions to support us in achieving our purpose and long-term goals."

Kapital Partner A/S
Kapital Partner is a Nordic Growth Market Mentor and Nasdaq Certified Adviser in Denmark and Sweden.  Read more about Kapital Partner at their website (https://kapitalpartner.dk/).